FDA's Ongoing User Fee System Upgrade Limits Payment Options
This article was originally published in The Pink Sheet Daily
Executive Summary
But it comes at a time when there is traditionally a lull in filings of generic drug applications.
You may also be interested in...
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
PDUFA Negotiations Begin With FDA Seeking Review System Reform
Fee structure changes and process enhancements floated during opening session between industry and agency.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.